Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Secures $12.5B Loan Agreements to Fund Purchase of Life Tech

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said after the close of the market on Tuesday that it has entered into a bridge credit agreement and a term loan agreement that together total $12.5 billion to help finance its proposed $13.6 billion acquisition of Life Technologies.

The bridge credit agreement is a 364-day unsecured committed bridge facility in the principal amount of $7.5 billion. The agreement is among the Thermo Fisher, an unnamed foreign subsidiary of the company, and several banks and other financial institutions, Thermo Fisher said in a document filed with the US Securities and Exchange Commission.

The institutions that have agreed to lend money to Thermo Fisher in connection to the bridge credit agreement include JP Morgan Chase Bank, Barclays Bank, Credit Suisse, Goldman Sachs, Citibank, and Morgan Stanley Senior Funding, among others.

The term loan agreement is a three-year unsecured term loan facility in the principal amount of $5.0 billion among Thermo Fisher, its unnamed foreign subsidiary, and several banks and other financial institutions.

Thermo Fisher's acquisition of Life Tech is expected to be completed in early 2014.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.